Diabetes remission in newly diagnosed type 2 diabetes mellitus through short-term continuous subcutaneous insulin infusion intensive therapy combined with low-carbohydrate diet treatment.

Publisher: Asian Association for the Study of Diabetes and Blackwell Pub. Asia Country of Publication: Japan NLM ID: 101520702 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2040-1124 (Electronic) Linking ISSN: 20401116 NLM ISO Abbreviation: J Diabetes Investig Subsets: MEDLINE

Original Publication: Tokyo : Asian Association for the Study of Diabetes and Blackwell Pub. Asia

Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/diet therapy ; Insulin*/administration & dosage ; Insulin*/therapeutic use ; Hypoglycemic Agents*/administration & dosage ; Hypoglycemic Agents*/therapeutic use ; Diet, Carbohydrate-Restricted* ; Insulin Infusion Systems*; Humans ; Male ; Female ; Middle Aged ; Blood Glucose/analysis ; Glycated Hemoglobin/analysis ; Infusions, Subcutaneous ; Remission Induction ; Adult ; Aged ; Combined Modality Therapy ; Treatment Outcome ; Prognosis ; Biomarkers/analysis

Aim/introduction: To evaluate the therapeutic efficacy short-term continuous subcutaneous insulin infusion (CSII) intensive therapy combined with a low-carbohydrate diet (LCD) for diabetes remission in patients with newly diagnosed type 2 diabetes mellitus.
Materials and Methods: This study included patients newly diagnosed with type 2 diabetes mellitus, who were randomly divided into two groups: conventional (conventional CSII + traditional lifestyle guidance); and intensive (intensive CSII + LCD lifestyle guidance). CSII was used for blood glucose control, with continuous glucose monitoring (CGM) used to monitor blood glucose levels. The primary outcome measure was hemoglobin A1c (HbA1c) level; secondary outcomes included body weight, body mass index (BMI), waist circumference, glycemic control, and biochemical indices.
Results: The time in range (TIR) in the intensive treatment group was greater than that in the conventional treatment group (P < 0.05). There was no significant difference in the incidence of hypoglycemia between the two groups (P > 0.05). Compared with the conventional treatment group, diabetes remission rates were significantly greater in the intensive treatment group (P < 0.05). In the intensive treatment group, fasting plasma glucose (FPG), HbA1c, Homeostasis Model assessment of Insulin Resistance (HOMA-IR), triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), and changes in body weight, BMI, visceral fat area (VFA), and subcutaneous fat area (SFA) decreased significantly (P < 0.05). FPG, HOMA-IR, TG, LDL-c, and changes in body weight, BMI, waist circumference, and VFA were significantly correlated with HbA1c levels (P < 0.05).
Conclusions: The combination of intensive CSII and LCD lifestyle guidance had been improved the remission rate in patients with newly diagnosed type 2 diabetes mellitus.
(© 2024 The Author(s). Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.)

JAMA. 2021 Jun 8;325(22):2262-2272. (PMID: 34077499)
Diabetologia. 2020 Feb;63(2):242-252. (PMID: 31701199)
Diabetes Metab Res Rev. 2016 Jan;32(1):21-39. (PMID: 25865292)
Diabetes Care. 2012 Mar;35(3):474-81. (PMID: 22228747)
Diabetes Care. 2023 Jan 1;46(Suppl 1):S97-S110. (PMID: 36507646)
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33. (PMID: 33298413)
Curr Med Res Opin. 2020 May;36(5):741-748. (PMID: 31990206)
Front Endocrinol (Lausanne). 2022 Apr 14;13:858912. (PMID: 35498416)
BMJ Nutr Prev Health. 2020 Nov 02;3(2):285-294. (PMID: 33521540)
Diabetes Res Clin Pract. 2015 May;108(2):250-7. (PMID: 25765670)
Ann Intern Med. 2017 Sep 19;167(6):365-374. (PMID: 28828487)
Nutr Diabetes. 2017 Dec 21;7(12):304. (PMID: 29269731)
Front Nutr. 2021 Aug 09;8:688540. (PMID: 34434951)
Diabetes Metab Syndr Obes. 2023 Apr 04;16:959-967. (PMID: 37038560)
Diabetes Technol Ther. 2019 Feb;21(2):81-85. (PMID: 30575414)
J Diabetes. 2023 Feb;15(2):133-144. (PMID: 36650669)
J Diabetes. 2017 Oct;9(10):890-893. (PMID: 28661564)
J Clin Endocrinol Metab. 2019 May 1;104(5):1520-1574. (PMID: 30903688)
J Diabetes Res. 2019 Aug 14;2019:8681959. (PMID: 31485454)
Diabetes Care. 2024 May 1;47(5):881-889. (PMID: 38489032)
Surg Today. 2022 Feb;52(2):287-293. (PMID: 34109448)
Am J Lifestyle Med. 2020 Jun 8;14(4):406-419. (PMID: 33281521)
Lancet Diabetes Endocrinol. 2013 Sep;1(1):28-34. (PMID: 24622264)
Diabet Med. 2021 May;38(5):e14528. (PMID: 33496979)
Can J Diabetes. 2021 Mar;45(2):137-143.e1. (PMID: 33039330)
Br J Nutr. 2021 Oct 14;126(7):1065-1075. (PMID: 33355062)
J Clin Endocrinol Metab. 2022 Jan 1;107(1):1-9. (PMID: 34459898)
Lancet. 2008 May 24;371(9626):1753-60. (PMID: 18502299)
Diabetes Care. 2019 May;42(5):731-754. (PMID: 31000505)
Ann Palliat Med. 2022 Apr;11(4):1462-1472. (PMID: 35523754)
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1829-1835. (PMID: 32961515)
Diabetes Care. 2022 Oct 1;45(10):2369-2375. (PMID: 35984478)
Diabetes Metab Syndr Obes. 2023 Nov 21;16:3751-3762. (PMID: 38028991)
JAMA. 2020 Jun 16;323(23):2397-2406. (PMID: 32543682)
BMJ. 2021 Jan 13;372:m4743. (PMID: 33441384)
J Diabetes Complications. 2022 Mar;36(3):108106. (PMID: 35131155)

2022012 Nanning Qingxiu District Science and Technology Plan Project; YNPY2023003 Research and Cultivation Project of First People's Hospital of Nanning; YN2024001 Research and Cultivation Project of First People's Hospital of Nanning; Z-A20221095 Health Self-financing Research Projects of Guangxi Zhuang Autonomous Region of China

Keywords: Continuous subcutaneous insulin infusion; Diabetes remission; Low‐carbohydrate diet

0 (Insulin)
0 (Hypoglycemic Agents)
0 (Blood Glucose)
0 (Glycated Hemoglobin)
0 (hemoglobin A1c protein, human)
0 (Biomarkers)

Date Created: 20241129 Date Completed: 20250301 Latest Revision: 20250426

20250428

PMC11871405

10.1111/jdi.14371

39610089